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SUMMARY
Background
Rectally administered mesalazine (mesalamine; 5-aminosalicylic acid) is
the first-line therapy for treatment of distal ulcerative colitis. Recently,
a high-volume 5-aminosalicylic acid foam has been shown to be as
effective and safe as standard 5-aminosalicylic acid enema.
Aim
To study the efficacy and safety of a low-volume vs. a high-volume
5-aminosalicylic acid foam.
Methods
In this investigator-blinded study, patients with active distal ulcerative
colitis [Clinical Activity Index (CAI) > 4, Endoscopic Index ‡ 4] were
randomized to receive 2 · 1 g ⁄30 mL low-volume (n = 163) or
2 · 1 g ⁄60 mL high-volume 5-aminosalicylic acid foam (n = 167) for
42 days. Primary end point was clinical remission (CAI £ 4) at the
final ⁄withdrawal visit (per-protocol).
Results
330 patients were evaluable for efficacy and safety by intention-to-treat,
290 for per-protocol analysis. Clinical remission rates at week 6 (per-pro-
tocol) were 77% on low-volume foam vs. 77% on high-volume foam
(P = 0.00002 for non-inferiority). The low-volume foam was associated
with a lower frequency of severe discomfort, pain and retention problems.
Conclusions
Low-volume 5-aminosalicylic acid foam is as effective and safe as a
high-volume 5-aminosalicylic acid foam in the treatment of active dis-
tal ulcerative colitis, but offers compliance advantages compared to the
high-volume preparation.
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INTRODUCTION
Ulcerative colitis (UC), a chronic inflammatory disease
of the colon, usually begins in the rectum and spreads
proximally via a continuous fashion. It is character-
ized by bloody diarrhoea, tenesm and abdominal
cramps, causing varying degrees of physical as well as
social disruption.
Salicylate type drugs are the treatment of choice in
mild-to-moderate UC.1–7 Rectal administration of such
drugs is the treatment of choice in proctitis, procto-
sigmoiditis and left-sided colitis.8–10 The rectal route is
of particular benefit since local concentrations of the
active drug are high, while systemic absorption is low.
Thus, both efficacy and tolerability are optimized.
Both, suppositories and enemas are widely used for
the treatment of distal UC. While suppositories are
effective only for proctitis, enemas will cover the
entire left colon. However, due to their sometimes
large volume, patients’ acceptance may be a problem
because of difficulties in self-administration, retention
and prolonged bed rest.
Recently, a high-volume (1 g ⁄ 60 mL) mesalazine
(mesalamine; 5-aminosalicylic acid, 5-ASA) foam has
been shown to be therapeutically equivalent to a
standard 5-ASA enema.11 Nevertheless, the totally
applied volume of 120 mL is still high and might cause
retention problems because of the release of foam under
high pressure and its quick expansion, leading to a
diminished acceptance and compliance of the patient.
In an effort to optimize further drug delivery and
patients’ compliance and acceptance, a new low-vol-
ume (1 g ⁄ 30 mL) 5-ASA foam formulation has been
developed, which releases the foam under a lower
pressure and thus might diminish severe retention
problems and thereby improves patients’ acceptance
and compliance. This low-volume 5-ASA foam was
already found to be well tolerated and superior to pla-
cebo in the treatment of distal UC.12 This study pre-
sents the head-to-head comparison of the efficacy and
safety of this low-volume vs. the high-volume 5-ASA
foam given for 6 weeks in patients with mild-to-mod-
erately active distal UC.
MATERIALS AND METHODS
Study design
This was a single-blind (investigator-blinded), random-
ized, multicentre, parallel-group clinical trial compar-
ing the efficacy and safety of a low-volume vs. a
high-volume 5-ASA foam in mild-to-moderately
active distal UC patients. The study was planned to be
performed according to a sequential adaptive design.
The first interim analysis was planned to be performed
after 200 intention-to-treat (ITT) evaluable patients
had finished the trial. The planned total sample size
was 296 patients. The study was conducted in 40 cen-
tres in six countries: Israel (13 centres), Germany
(nine), Hungary (seven), Lithuania (six), Latvia (three)
and Estonia (two). Patients were assigned to the treat-
ment groups based on a computer-generated randomi-
zation scheme. Because of the differences in the
appearance of both foam cans, the distribution of
study medication and handling of returned study med-
ication was performed by a third person at each cen-
tre, who was not involved in any assessment, thus all
investigators as well as the central pathologist were
blinded to the formulation given. Treatment lasted
6 weeks, with control visits at 2 and 4 weeks. Patients
were enrolled from March 2004 to March 2005. A
sponsor-independent data monitoring committee
reviewed unblinded data of the interim analyses. The
study was conducted in accordance with GCP and the
Declaration of Helsinki, and was approved by indepen-
dent ethics committees for each of the centre.
Patients
Men and women aged 18–75 years with established or
newly diagnosed active distal UC (maximum 40 cm
from anus) confirmed by endoscopy, histology and
negative stool cultures, and a Clinical Activity Index
(CAI) > 4 and Endoscopic Index (EI) ‡ 4 (both accord-
ing to Rachmilewitz) were allowed to be included.13
Major exclusion criteria were: Crohn’s disease, renal or
liver insufficiency, steroids within 1 month and immu-
nosuppressants within 3 months prior to baseline,
relapse under daily maintenance of >1 g rectal or >2 g
oral 5-ASA, or corresponding doses of rectal or oral
sulfasalazine, concomitant use of NSAIDs for >2 weeks,
antibiotics, psyllium containing drugs or loperamide.
All oral or rectal treatments for UC were stopped at
baseline. All patients had to give their written informed
consent prior to their participation in this study.
Study medications
The test product was the low-volume (1 g ⁄ 30 mL)
5-ASA foam (Salofalk 1 g foam), manufactured by
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Dr Falk Pharma GmbH (Freiburg, Germany). The refer-
ence product was a high-volume (1 g ⁄ 60 mL) 5-ASA
foam (Claversal Rektalschaum), manufactured by Merc-
kle Recordati GmbH (Ulm, Germany). Two puffs of the
respective foam were to be administered once daily in
the evening, if possible after defecation, resulting in a
total foam volume of 60 (Salofalk 1 g foam) and
120 mL (Claversal Rektalschaum), respectively.
Procedures
At baseline, patients were physically examined and
their demographics and medical history were recorded.
Vital signs and laboratory tests, including haematolo-
gy, biochemistry and urinalysis, were assessed at each
visit. Clinical disease activity was primarily assessed at
each visit using the CAI according to Rachmilewitz.13
Disease was classified as mild if baseline CAI was £8
and as moderate if CAI >8. As a secondary efficacy
score the Disease Activity Index (DAI) according to
Sutherland was assessed at baseline and final visit.14
The disease activity was also assessed endoscopically,
by the same investigator at baseline and final visit,
using the EI.13 Biopsy specimens were taken at base-
line and end of treatment, from the most inflamed
area from the rectum and sigmoid, respectively, and
were separately examined by a central pathologist,
who was blinded to treatment, to determine the Histo-
logical Index (HI) according to Riley.15 The total HI
was based on the most severely inflamed segment. In
addition, the physicians’ global assessment (PGA) of
efficacy was assessed at week 6.16 Concomitant medi-
cations and adverse events (AEs) were recorded at each
visit. Both patients and investigators gave their global
assessment of tolerability of study medication (‘very
good’, ‘good’, ‘satisfactory’ or ‘poor’) at the final
visit.11, 12
Patient diaries
The number of bowel movements, presence of rectal
bleeding, abdominal pain and cramps, and general
well-being were daily recorded in a diary. In addition,
the patient was asked to assess the handling and appli-
cation of the study medication with respect to follow-
ing items: ‘Discomfort during administration’,
‘problems in retaining the study drug’, ‘rectal ⁄ abdomi-
nal pain during administration’, ‘abdominal bloating
during ⁄ after administration’ and to rate each item on
a 5-point scale (‘no problems’, ‘little problems’, ‘mod-
erate problems’, ‘considerable problems’ and ‘severe
problems’). Treatment compliance was assessed on the
regular use of the study medication as recorded by the
patient on a daily basis in the diary and by weighing
the returned foam cans.
Primary objective and efficacy variable
The primary objective was to test the non-inferiority
of the low-volume vs. the high-volume 5-ASA foam,
with respect to clinical remission (defined by CAI £ 4)
at the final visit [with last observation carried forward
(LOCF) and a non-inferiority margin of 20% (one-sided
a = 0.025)]. Exploratory subgroup analyses were fixed
in the protocol and included analyses by gender, dura-
tion of the disease (£5 years vs. >5 years), baseline
severity (CAI £ 8 vs. CAI > 8), and extent of disease
(proctitis vs. proctosigmoiditis).
Secondary efficacy variables
Secondary efficacy end points included the CAI in the
course of the study; clinical improvement at final visit
(LOCF) based on the CAI (i.e. ‡1 point decrease from
baseline); clinical remission based on the DAI [i.e. <4
at final visit (LOCF)]; mean change from baseline to
final visit (LOCF) in the CAI, DAI and EI scores as well
as in the number of stools and bloody stools per week;
time to first resolution of symptoms defined as no
more than three stools per day – all without blood;
therapeutic success (i.e. PGA: ‘complete relief’ or
‘marked improvement’) and therapeutic benefit (i.e.
PGA of at least ‘slight improvement’) at the final visit;
endoscopical remission defined as an EI of <4 at the
final visit (LOCF); mucosal healing defined as a
DAImucosal subscore of £1 at final visit (LOCF) and his-
tological remission defined as a HI of 1 at the final
visit (LOCF).
Safety variables
For the safety population, the frequency of AEs and
clinically relevant changes in laboratory parameters
and vital signs were assessed.
Statistical analysis
For proving therapeutic equivalence (non-inferiority)
of low-volume vs. high-volume 5-ASA foam, a one-
sided test hypothesis was used. The non-inferiority
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margin was predefined as )20% for the difference of
remission rates between treatments. Assuming a remis-
sion rate of 60% under treatment with low-volume
foam vs. 64% under high-volume 5-ASA foam, a sam-
ple size of 148 patients in each treatment arm was cal-
culated to achieve a 80% power to yield a statistical
significant result. As the study was conducted using a
4-stage group sequential test design,17, 18 the boundary
P-value at the first interim analysis was given as
P1 = 0.00570, thus the overall type I error rate of
a = 0.025 (one-sided) was maintained.19, 20 For confir-
mative proof of non-inferiority, the rate of clinical
remission was tested using a v2 test with maximum
likelihood estimation according to Farrington and
Manning,21 and differences between the remission rates
and corresponding 97.5% one-sided repeated confi-
dence intervals (CIs) were provided.22 The confirmatory
test was based on the per-protocol (PP) analysis set.
For sensitivity analysis the ITT analysis was performed.
All other group comparisons were of exploratory nat-
ure. For evaluation of secondary efficacy end points,
95% CIs were calculated for the differences between
the two treatment groups (low- vs. high-volume foam).
The median time to first symptomatic remission, in
days, and the corresponding 95% CI was calculated for
each treatment group using Kaplan–Meier estimation.
Treatment groups were compared by calculating the




A total of 330 patients were enrolled and randomized
(low-volume foam: 163; high-volume foam: 167).
There were no statistically significant differences
between the treatment groups regarding the demo-
graphic variables, baseline disease characteristics or
prestudy medication (Table 1).
Treatment compliance and protocol violations
All patients were treated and thus were evaluated in
the safety and ITT population. The mean (s.d.) compli-
ance to study drug administration per patient
amounted to 97% (6%) in the low-volume and 95%
(9%) in the high-volume foam group, respectively (ITT
population). A total of 40 patients (low-volume foam:
17; high-volume foam: 23) were excluded from the PP
population due to major protocol deviations (low-vol-
ume foam: 13; high-volume foam: 15), non-compli-
ance (low-volume foam: 3; high-volume foam: 8) or
premature study termination for reasons other than
lack of efficacy or drug-related AEs (low-volume
foam: 5; high-volume foam: 10). Thus, the PP popula-
tion consisted of 290 patients.
The criteria used for exclusion from the PP data
set were stated in the statistical analysis plan before
breaking the blind. Major protocol deviations were
almost equally distributed among the treatment
groups. The most frequent major protocol violation
was non-confirmation of UC (low-volume foam: 7;
high-volume foam: 8) by the blinded, central pathol-
ogist. In 10 of these 15 patients, the disease was
either newly diagnosed at baseline (by the central
pathologist) or diagnosed within the very last few
weeks or months prior to baseline by a local patholo-
gist. Considerably more patients in the group receiv-
ing high-volume foam were excluded from PP
analysis because of non-compliance or premature
study termination caused by reasons other than lack
of efficacy or drug-related AEs. The disposition of
the patients enrolled in the study is provided in
Figure 1.
Primary efficacy evaluation
Clinical remission at study end (LOCF) – based on
CAI
Already at the first interim analysis, performed after
approximately the first 200 ITT-evaluable patients,
the test on non-inferiority of the two remissions rates
[low-volume foam: 73%; high-volume foam: 74%;
with difference of proportions (95% CI): )0.7%
()17.2% to 16.1%)] yielded a one-sided observed
P-value of 0.00153 for the PP analysis set. Therefore,
the recruitment of the study was stopped as non-
inferiority was confirmatively proven. The final anal-
ysis of all 330 randomized patients confirmed the
results of the interim analysis with an even more
stringent 95% CI for the difference between the
remission rates (low-volume foam: 77%; high-volume
foam: 77%, see Figure 2). The clinical remission rates
at the final ⁄ withdrawal visit did not show any differ-
ence between treatment groups in the PP population,
but were slightly higher in the low-volume foam-
than in high-volume foam-treated patients in the ITT
population.
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Influence of covariates on clinical remission
The predefined exploratory subgroup analyses of the
primary end point are presented for the ITT population
in Table 2. Gender evaluation of the clinical remission
rates showed no statistically significant differences
between male and female patients, indicating that rec-
tal 5-ASA seems to be equally effective in male and
female patients. However, it should be noted that in
contrast to the low-volume foam group in which
males and females showed very similar remission rates
(74% vs. 77%), less male patients in the high-volume
foam group experienced clinical remission compared
with females in this group (65% vs. 78%). Patients






Male 80 (49) 69 (41)
Female 83 (51) 98 (59)
Ethnic origin [Caucasian, n (%)] 163 (100) 167 (100)
Age [years; mean (s.d.)] 43.9 (15.4) 42.0 (13.9)
Weight [kg; mean (s.d.)] 74.0 (15.0) 71.4 (14.1)
Smoking habits, n (%)
Non-smoker 118 (72) 120 (72)
Ex-smoker 33 (20) 27 (16)
Smoker 12 (7) 20 (12)
Duration of the disease [years; median (range)] 4.2 (0.1–32.9) 3.5 (0.1–45.5)
Type of disease, n (%)
New diagnosis 39 (24) 52 (31)
Established disease 124 (76) 115 (69)
Extraintestinal manifestations in the past
(established disease)
22 (18%) [n = 124] 14 (12%) [n = 115]
Course of the established disease, n (%)
Chronically active disease 6 (5) [n = 124] 9 (8) [n = 115]
Relapsing disease 118 (95) [n = 124] 106 (92) [n = 115]
Localization of the disease, n (%)
Proctitis 91 (56) 85 (51)
Proctosigmoiditis 72 (44) 82 (49)
Number of previous episodes
[relapsing disease; mean (s.d.)]
5.0 (6.4) [n = 117] 4.4 (4.6) [n = 105]
Duration of last remission phase [relapsing disease;
years; median (range)]
0.7 (0.0–14.3) [n = 118] 0.9 (0.0–8.9) [n = 106]
Duration of present acute episode [relapsing disease;
days; median (range)]
35.0 (3.0–687.0) [n = 118] 36.5 (5.0–352.0) [n = 106]
Prestudy maintenance medication*, n (%) 51 (43) [n = 118] 50 (47) [n = 106]
Oral 5-ASA, n (%) 34 (29) 37 (35)
Rectal 5-ASA, n (%) 14 (12) 8 (8)
Oral sulfasalazine, n (%) 7 (6) 10 (9)
Oral corticosteroids, n (%) 1 (0.8) 1 (0.9)
Length of inflammation [cm; mean (s.d.)] 22.6 (9.8) 22.9 (10.2)
CAI, mean (s.d.) 7.3 (1.7) 7.6 (1.9)
Severity of the disease, n (%)
Mild (CAI £ 8) 128 (76) 126 (76)
Moderate (CAI > 8) 35 (25) 40 (24)
DAI, mean (s.d.) 7.1 (1.9) 7.3 (1.9)
EI, mean (s.d.) 7.5 (1.7) 7.5 (1.8)
CAI, Clinical Activity Index; DAI, Disease Activity Index; EI, Endoscopic Index; 5-ASA, 5-aminosalicylic acid.
* Doses of the prestudy medication did not violate the exclusion criterion.
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with a longer disease duration (>5 years) showed a
slightly lower response to treatment (74% vs. 82% in
the low-volume and 70% vs. 83% in the high-volume
group, respectively) compared to those with a shorter
disease duration; an observation which was also found
in other trials of distal UC.23 With respect to baseline
severity, there was no difference in the remission rates
between mild and moderately active patients in the
low-volume foam group (76% vs. 74%). However,
there was a clear difference seen in the high-volume
foam group, i.e. patients with mild disease at baseline
showed remission rates (78%) which were comparable
to those in the low-volume foam group, whereas mod-
erately active patients showed substantially lower
remission rates (58%) (P = 0.012; v2 test, two-sided).
The PP population showed nearly identical results.
Secondary efficacy evaluation
The results of the ITT population presented below were
nearly identical to the ones observed in the PP popula-
tion.
CAI
In addition to the three quarters of patients showing
clinical remission at week 6 (LOCF), 15% of the
patients in both treatment groups showed a clinical
improvement. With regard to clinically relevant sub-
scores of the CAI at week 6 (LOCF), 64% and 57% of
the patients in the low-volume and high-volume foam
group, respectively, showed normalization in the num-
ber of stools, and 68% vs. 64% a complete disappear-
ance of blood in their stools. Improvement in the
number of stools was observed in further 12% and
PP population
n = 146
Withdrawals n = 16
• Lack of efficacy n = 9
• Lack of patient's co-operation n = 2
• AE/SAE n = 4
• Other n = 1
Completed study
n = 149
Withdrawals n = 18
• Lack of efficacy n = 8
• Lack of patient's co-operation n = 8
• AE/SAE n = 1













Figure 1. Patient disposition.
AE, adverse event; ITT, inten-
tion-to-treat; PP, per-protocol;













































(Low-high-volume)  (95% CI)
Figure 2. Clinical remission rates (CAI £ 4) at week 6
(LOCF) at the final analysis of all randomized patients.
ITT, intention-to-treat; LOCF, last observation carried for-
ward; PP, per-protocol; CAI, Clinical Activity Index.
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14% of the patients in the low-volume and high-vol-
ume foam group, and an improvement in the number
of bloody stools in further 7% and 11%, respectively.
A total of 45% of the patients in both treatment
groups showed a normalization, and additionally 15%
showed an improvement in their general well-being.
In line with the above assessments, about 55% and
18% of patients each in both treatment groups had no
abdominal pain or at least an improvement at study
end, respectively.
The course of the CAI during the study (Figure 3), as
well as the mean change from baseline in the CAI was
nearly identical between both treatment groups
(Table 4), indicating also the therapeutic equivalence
of both drugs.
Time to first resolution of symptoms
The median time to first resolution of symptoms and
the hazard ratios and their 95% CIs were nearly identi-
cal between both groups (Table 3).
Table 2. Clinical remission
rates (CAI) by baseline covari-
ates (intention-to-treat)
Number (%) of patients in clinical remission
(CAI £ 4) at final visit (LOCF)
Low-volume
foam (n = 163)
High-volume
foam (n = 167)
Adjusted odds
ratio* (95% CI)
All 123 (76) 121 (73) 1.17 (0.71–1.91)
Gender
Male 59 ⁄ 80 (74) 45 ⁄ 69 (65) 1.21 (0.74–1.98)
Female 64 ⁄ 83 (77) 76 ⁄ 98 (78)
Duration (years)
£5 27 ⁄ 33 (82) 30 ⁄ 36 (83) 1.18 (0.72–1.94)
>5 96 ⁄ 130 (74) 91 ⁄ 131 (70)
Severity (CAI at baseline)
£8 points (mild disease) 97 ⁄ 128 (76) 98 ⁄ 126 (78) 1.13 (0.69–1.85)
>8 points (moderate disease) 26 ⁄ 35 (74) 23 ⁄ 40 (58)
Disease location
Proctitis 71 ⁄ 91 (78) 64 ⁄ 85 (75) 1.15 (0.70–1.89)
Proctosigmoiditis 52 ⁄ 72 (72) 57 ⁄ 82 (70)
CAI, Clinical Activity Index; CI, confidence interval; LOCF, last observation carried for-
ward.
* Odds ratio for treatment groups low-volume vs. high-volume foam, adjusted for



















Low-volume foam High-volume foam
Figure 3. Course of the mean Clinical Activity Index dur-
ing the study (ITT). ITT, intention-to-treat; LOCF, last
observation carried forward.
Table 3. Time to first resolution of symptoms (time to
event analysis)
Median time to first resolu-










PP 6.0 6.0 1.090 0.851–1.397
ITT 6.0 7.0 0.987 0.780–1.248
ITT, intention-to-treat, PP, per-protocol.
* Defined as no more than three stools per day – all without
blood.
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Clinical remission at study end (LOCF) – based on
DAI (secondary efficacy end point)
As a secondary efficacy end point, clinical remission
was assessed by using the DAI score. Although the
mean remission rates were slightly higher [105 of 157
patients (67%)] in the low-volume foam group com-
pared with those in the high-volume foam group [99
of 162 patients (61%); see Figure 4], the mean change
from baseline in the DAI did not differ between the
treatment groups (Table 4), thus confirming the thera-
peutic equivalence of both drugs.
Endoscopic Index and Mucosal Healing (DAI)
A total of 59% and 62% of the patients in the low-vol-
ume and high-volume foam group, respectively, were in
endoscopical remission at the final visit (LOCF; see
Figure 4). An improvement in the EI was observed in
further 18% and 17% of the patients in the low-volume
and high-volume foam group, respectively. Also, the
mean change from baseline in the EI was not signifi-
cantly different between both treatment groups (Table 4).
Mucosal healing in the low-volume foam and high-
volume foam group was observed in 116 of 163
patients (71%; 95% CI: 64.2–78.1%) and 118 of 167
patients (71%; 95% CI: 63.8–77.6%) in the ITT popula-
tion, respectively (Figure 4), thus was nearly identical
between both treatment groups.
Histological Index
Five patients in the low-volume foam group and four
patients in the high-volume foam group, all with
histological signs of acute UC at baseline recovered
completely at the final visit (i.e. HI = 0). About half
Table 4. Change from baseline to final visit (LOCF) in secondary efficacy end points (intention-to-treat population)





(P-value)Low-volume foam High-volume foam
CAI )4.7 (3.1) )4.8 (3.0) 0.2 ()0.5 to 0.8) 0.6089
DAI )4.4 (2.6) )4.4 (2.3) 0.1 ()0.5 to 0.6) 0.8481
EI )4.1 (3.0) )4.5 (2.8) 0.4 ()0.3 to 1.0) 0.2450
Number of stools ⁄ week )14.0 (14.7) )13.1 (16.3) )0.8 ()4.2 to 2.5) 0.6264
Number of bloody stools ⁄ week )17.1 (14.6) )17.4 (16.9) 0.3 ()3.2 to 3.7) 0.8816
CAI, Clinical Activity Index; CI, confidence interval; DAI, Disease Activity Index; EI, Endoscopic Index; LOCF, last observation
carried forward.














































































































































Low-volume foam High-volume foam
Figure 4. Secondary efficacy
end points at week 6 [LOCF;
(ITT)]. DAI, Disease Activity
Index; EI, Endoscopic Index;
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the patients in both treatment groups showed a histo-
logical remission (HI = 1) at the final visit [low-vol-
ume foam (N = 136): 52%; high-volume foam
(N = 140): 46%; see Figure 4]. Improvement in the HI
was observed in approximately another quarter of the
patients in both treatment groups [low-volume foam
(N = 136): 24%; high-volume foam (N = 140): 26%].
Only one patient in the high-volume foam group had
a deterioration in his HI compared to baseline.
Physician’s Global Assessment
A total of 30% and 31% of the patients in the low- and
high-volume foam group, respectively, reported com-
plete relief of symptoms at the final visit; a marked
improvement in symptoms was indicated by further
42% and 40% of the patients in both treatment groups.
The proportion of patients with a moderate and slight
improvement in symptoms were 7% each in the low-
volume foam group, and 10% and 6% in the high-vol-
ume foam group, respectively. In the low- and high-
volume foam group, 72% and 70% of the patients
achieved therapeutic success and 86% and 86%,
respectively, had a therapeutic benefit (see Figure 4).
Change from baseline in secondary efficacy end
points
In general, no statistically significant or clinically
meaningful differences in the mean change from base-
line between both treatment groups were observed
with regard to any of the secondary efficacy scores
presented in Table 4.
Handling and application of the study drug
The vast majority of the patients in both treatment
groups rated the handling and application of the foam
as ‘easy’ or ‘not too difficult’. Only 4% of all patients
in the low-volume and 11% in the high-volume foam
group assessed the handling as ‘difficult’ (ITT). In line
with this finding, statistically more patients in the
high-volume foam group reported considerable or
severe problems regarding abdominal pain, retention
and discomfort during administration when adminis-
trating the foam (see Table 5).
Adverse events
In total, 100 AEs were reported by 63 patients (39%)
in the low-volume foam group, and 96 AEs by 62
patients (37%) in the high-volume foam group. The
number of patients experiencing AEs, which were con-
sidered to be potentially drug-related (ADRs), were 13
(8%) in the low-volume foam and eight (5%) in the
high-volume foam group.
Most frequently reported system organ classes were:
gastrointestinal disorders, nervous system disorders,
general disorders and administration site conditions, as
well as infections and infestations (see Table 6).
Table 5. Problems during
administration of the foam
(intention-to-treat population)
Number (%) of patients reporting
considerable severe or severe prob-




foam (n = 163)
High-volume
foam (n = 167)
Problems in retaining 17 (10) 31 (19) 0.0361
Considerable severe 12 (7) 21 (13)
Severe 5 (3) 10 (6)
Discomfort during administration 4 (3) 15 (9) 0.0109
Considerable severe 4 (3) 9 (5)
Severe – 6 (4)
Pain during administration 3 (2) 11 (7) 0.0325
Considerable severe 2 (1) 8 (5)
Severe 1 (0.6) 3 (2)
LOCF, last observation carried forward.
* Low-volume foam ) high-volume foam.
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The vast majority of patients experienced AEs of
mild (low-volume foam: 31%; high-volume foam:
29%) or moderate intensity (low-volume foam: 10%;
high-volume foam: 11%). Adverse events of severe
intensity occurred only in four patients of the low-vol-
ume foam group and in two patients of the high-vol-
ume foam group (most often ‘colitis aggravated’). In
total, four AEs, which were, due to the subsequent
hospitalization, rated as serious (SAEs), occurred in
four patients [low-volume foam: one patient (colitis
aggravated); high-volume foam: two patients (colitis
aggravated), one patient (total thyroidectomy)]. None
of these SAEs was related to the study drug. No death
occurred during this study. Eight AEs led to with-
drawal of the study drug in seven patients treated with
low-volume foam and five AEs led to withdrawal of
the study drug in five patients treated with high-vol-
ume foam. ‘Colitis aggravation’ was the most frequent
MedDRA term for withdrawal in both groups. All these
patients recovered completely or were recovering
during the follow-up period under treatment with sys-
temic corticosteroids.
DISCUSSION
This is the first randomized, single-blinded clinical
trial comparing head-to-head the efficacy and tolera-
bility of a new low-volume (1 g ⁄ 30 mL) vs. a high-
volume (1 g ⁄ 60 mL) 5-ASA foam. It was conducted to
demonstrate the non-inferiority of the low-volume
foam (Salofalk 1 g foam) to the high-volume foam
(Claversal foam) with respect to induction of clinical
remission in patients with active ulcerative proctitis or
proctosigmoiditis.
At the final analysis of all 330 included patients, the
clinical remission rates based on the CAI in the PP
and ITT population were 77% in both treatment groups
in the PP population, and 76% (low-volume) and 73%
(high-volume) in the ITT population, respectively. The
achieved lower boundaries of the 95% CI of the differ-
ence between proportions of the low- vs. the high-vol-
ume foam in the PP and ITT population were )9% and
)7%, respectively, and thus indicating very robust
data. Moreover, the rates for remission and improve-
ment in the secondary end points (DAI, EI, HI and
PGA) did not show any significant differences between
the treatment groups. Similar to the primary end point,
the remission rates in the low-volume foam group
were, both in the ITT and in the PP population, nearly
in all secondary end points numerically even slightly
higher than the ones in the high-volume foam group,
giving further proof that the low-volume foam is non-
inferior to the high-volume foam. The achieved clini-
cal remission rate for the low-volume foam in this
trial (ITT: 76%) was even slightly better than the ones
reported in previous trials with this foam: SAF-4 (ITT:
65%),12 SAF-3 (ITT: 62%; remission defined as CAI
<4).24
The trial results provide further insight into the
question of rectal 5-ASA daily dose: given the high
and rapid response observed in this trial, a daily
dose of 2 g rectal 5-ASA is appropriate for the treat-
ment of mild-to-moderate active proctosigmoiditis.
Rectal 5-ASA induces mucosal healing in a substan-
tial proportion of patients (approximately 70%) with
mild-to-moderate active proctosigmoiditis. As muco-
sal healing is a predictor for risk reduction of colo-
rectal cancer in UC,25 this might partially explain the
beneficial role of 5-ASA as a chemopreventative in
UC.26
Table 6. Patients with at least one AE (safety population)
System organ class (MedDRA)
Number (%) of patients







Gastrointestinal disorders 25 (15) 22 (13)
Nervous system disorders 15 (9) 18 (11)
Infections and infestations 18 (11) 10 (6)
General disorders and
administration site conditions
7 (4) 8 (5)
Investigations 7 (4) 5 (3)
Musculoskeletal and connective
tissue disorders
4 (3) 5 (3)
Skin and subcutaneous
tissue disorders
4 (3) 2 (1)
Respiratory, thoracic and
mediastinal disorders
2 (1) 4 (2)
Reproductive system and
breast disorders
1 (0.6) 4 (2)
Hepatobiliary disorders 1 (0.6) 2 (1)
Psychiatric disorders 1 (0.6) 2 (1)
Injury, poisoning and
procedural complications
0 (0) 2 (1)
Renal and urinary disorders 1 (0.6) 0 (0)
Cardiac disorders 0 (0) 1 (0.6)
Surgical and medical procedures 0 (0) 1 (0.6)
Vascular disorders 0 (0) 1 (0.6)
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Endoscopic remission rates were remarkably similar
between the current trial (ITT: 59%), and previous tri-
als with the low-volume foam – SAF-4 (ITT: 57%)12
and SAF-3 (57%; EI <6; assessed after 3 weeks).24
These excellent efficacy data confirm the role of rectal
5-ASA therapy as a first choice strategy for the induc-
tion of remission in active distal UC, which is recom-
mended by several guidelines.1, 4, 5
As the data confirm in a strong sense that both
galenic 5-ASA foam preparations are equally effec-
tive in inducing remission in patients with mild-to-
moderately active distal UC, the speculations about a
potential superiority of the high-volume foam as dis-
cussed by Malchow et al. were obviously false.11
However, as the entry criteria and the primary end
point used in the current trial and the one published
by Malchow et al., are slightly different, we explora-
tively analysed our current data according to the def-
inition used by Malchow et al., to prove the
robustness of our data. In the study of Malchow
et al., patients with established, recurrent disease
were recruited, who had baseline sum score of the
first four subscores of the CAI (CAI1–4) ‡ 4; the pri-
mary end point (PP population) was defined as a
CAI1–4 £ 2 after 4 weeks of treatment (LOCF).11 Using
these definitions, 57 of 109 patients (52%) in the
low-volume and 49 of 98 patients (50%) in the high-
volume foam group came into clinical remission.
Even if the remission rates with this definition were
slightly lower compared with the ones reported by
Malchow et al., there was no statistical difference
between both remission rates in this study.
Subgroup analysis showed that disease severity had
no influence on the remission rates of the low-volume
foam. The low-volume foam was equally effective
both in mild (76%) and in moderate (74%) disease. In
contrast, the high-volume foam had significantly less
favourable results in moderate (58%) compared with
mild disease (78%; P = 0.012; v2 test, two-sided).
Furthermore, disease extent had no impact on the
treatment response. The low-volume foam and the
high-volume foam worked reliably both in proctitis
and proctosigmoiditis.
Both foam preparations induced a rapid resolution
of clinical symptoms, which seems to be superior to
oral 5-ASA preparations.27, 28 This finding confirms
that a rectal 5-ASA preparation, or even a combina-
tion of oral ⁄ rectal 5-ASA,29 is the treatment of
choice, when the extent of the UC is limited to the
distal part of the colon. Moreover, as the 5-ASA
plasma levels after rectal administration are lower
than after oral intake,30 a rectal administration pro-
vides an even better benefit ⁄ risk ratio for the treat-
ment of distal UC.
Rectal 5-ASA administered either as a low-volume
or a high-volume foam was found to be safe in this
short-term trial, which is fully compatible with the
published experience,11, 12, 14, 31 as are the type and
frequency of AEs.
The main reason for the development of a rectal
5-ASA foam is that foam preparations in general are
easier to retain and are interfering less with daily rou-
tine than liquid enemas and hence are the preferred
rectal formulation.12, 23, 32 This finding was impres-
sively confirmed in this trial. Considerable up to severe
problems during the administration of a rectal product
might have an impact on the long-term compliance to
the treatment of such a patient. Interestingly, statisti-
cally significant less patients in the low-volume foam
group reported considerable or severe pain or discom-
fort during the administration, or had considerable or
severe problems in retaining the drug. These might be
attributable to differences in the device (i.e. less rigid,
lubricated applicator) and the lower volume per puff of
the low-volume foam. Such advantages in application
and convenience can contribute to further improve-
ment in patients’ adherence to previously fairly unpop-
ular rectal treatment regimens in distal UC.
We conclude that the novel low-volume 5-ASA
foam is a strongly effective and well-tolerated prepa-
ration, which has some advantages in patients’ conve-
nience compared to the comparator. This new
preparation could extend patients’ adherence to topical
treatment.
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